Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia: a 12-week, randomised, double-blind, parallel-group, placebo controlled, international multicentre study.

Trial Profile

Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia: a 12-week, randomised, double-blind, parallel-group, placebo controlled, international multicentre study.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Aladorian (Primary)
  • Indications Ventricular arrhythmias
  • Focus Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 28 Feb 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 29 Nov 2012 Planned end date changed from 31 Dec 2011 to 28 Feb 2013 as reported by ISRCTN: Current Controlled Trials.
    • 29 Nov 2012 Status changed from completed to recruiting as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top